Royal Bank of Canada Boosts Pyxis Oncology (NASDAQ:PYXS) Price Target to $10.00

Pyxis Oncology (NASDAQ:PYXS) had its target price lifted by Royal Bank of Canada from $7.00 to $10.00 in a research note released on Thursday morning,Benzinga reports. They currently have an outperform rating on the stock.

A number of other research firms have also recently commented on PYXS. HC Wainwright reissued a “buy” rating and set a $7.00 price target on shares of Pyxis Oncology in a report on Thursday. Stifel Nicolaus began coverage on Pyxis Oncology in a research note on Thursday, August 8th. They issued a “buy” rating and a $10.00 target price on the stock. William Blair lowered shares of Pyxis Oncology from an “outperform” rating to a “market perform” rating in a report on Thursday. Finally, Stephens started coverage on Pyxis Oncology in a research report on Friday, November 8th. They set an “overweight” rating and a $13.00 price target on the stock. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, Pyxis Oncology presently has an average rating of “Moderate Buy” and an average target price of $10.00.

Pyxis Oncology Stock Down 9.5 %

Shares of NASDAQ PYXS opened at $1.90 on Thursday. Pyxis Oncology has a 52-week low of $1.35 and a 52-week high of $6.85. The company has a market cap of $112.99 million, a PE ratio of -1.84 and a beta of 1.27. The firm’s 50-day moving average price is $3.64 and its 200-day moving average price is $3.61.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of PYXS. Fullcircle Wealth LLC acquired a new position in shares of Pyxis Oncology during the second quarter valued at approximately $40,000. SG Americas Securities LLC acquired a new stake in shares of Pyxis Oncology in the first quarter valued at $59,000. Intech Investment Management LLC acquired a new position in Pyxis Oncology during the 3rd quarter worth about $55,000. MetLife Investment Management LLC lifted its holdings in Pyxis Oncology by 41.1% during the 3rd quarter. MetLife Investment Management LLC now owns 18,818 shares of the company’s stock worth $69,000 after buying an additional 5,484 shares in the last quarter. Finally, The Manufacturers Life Insurance Company acquired a new position in Pyxis Oncology during the 2nd quarter worth $65,000. Institutional investors and hedge funds own 39.09% of the company’s stock.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.